Liu Juncai, Zhu Hongjing, Jiang Huijuan, Zhang Hongzhi, Wu Dapeng, Hu Xigang, Zhang Huxiang
Department of Radiotherapy, Huaihe Hospital of Henan University, Henan, Kaifeng 475000, China.
J Cancer Res Ther. 2015 Aug;11 Suppl 1:C104-6. doi: 10.4103/0973-1482.163857.
The purpose of this study was to evaluate the value of tumor M2 pyruvate kinase (tumor M2-PK) in the diagnosis of nonsmall cell lung cancer.
The diagnosis clinical studies of tumor M2-PK in the diagnosis of nonsmall cell lung cancer were electronic researched in the Medline, EMBASE, WANFANG, and CNIK databases. The data of true positive, false positive, false negative, and true negative were extracted from each of the individual studies. We use Stata11.0 (http://www.stata.com; Stata Corporation, College Station, TX) and MetaDiSc 1.4 software to pool the diagnostic sensitivity, specificity, and diagnostic area under the receiver operating characteristic (ROC).
Eleven diagnostic clinical studies with 1294 subjects were included in this diagnostic meta-analysis. The combined sensitivity, specificity, positive likely hood ratio, negative likely hood ratio were 0.69 (0.65-0.72), 0.92 (0.89-0.94), 7.84 (5.92-10.38), 0.36 (0.32-0.40). And the area under the ROC curve was 0.92 (0.90-0.94).
Serum tumor M2-PK can be a potential biomarker for diagnosis of nonsmall cell lung cancer.
本研究旨在评估肿瘤M2丙酮酸激酶（tumor M2-PK）在非小细胞肺癌诊断中的价值。
通过在Medline、EMBASE、万方和中国知网数据库中进行电子检索，获取肿瘤M2-PK诊断非小细胞肺癌的诊断性临床研究。从每项独立研究中提取真阳性、假阳性、假阴性和真阴性数据。我们使用Stata11.0（http://www.stata.com；Stata公司，德克萨斯州大学城）和MetaDiSc 1.4软件汇总诊断敏感性、特异性以及受试者工作特征（ROC）曲线下的诊断面积。
本诊断性荟萃分析纳入了11项诊断性临床研究，共1294名受试者。合并敏感性、特异性、阳性似然比、阴性似然比分别为0.69（0.65 - 0.72）、0.92（0.89 - 0.94）、7.84（5.92 - 10.38）、0.36（0.32 - 0.40）。ROC曲线下面积为0.92（0.90 - 0.94）。
血清肿瘤M2-PK可作为诊断非小细胞肺癌的潜在生物标志物。
